Emmaus Life Sciences Inc
OTC:EMMA
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Emmaus Life Sciences Inc
OTC:EMMA
|
US |
|
S
|
Svenska Aerogel Holding AB (publ)
STO:AERO
|
SE |
|
I
|
Integrum AB
STO:INTEG B
|
SE |
|
H
|
Hengdian Entertainment Co Ltd
SSE:603103
|
CN |
|
Luxshare Precision Industry Co Ltd
SZSE:002475
|
CN |
|
Mitsubishi Corp
TSE:8058
|
JP |
|
Fuse Group Holding Inc
OTC:FUST
|
US |
|
Megastar Foods Ltd
NSE:MEGASTAR
|
IN |
|
Samson Holding Ltd
HKEX:531
|
HK |
|
F
|
Fad International Co SJSC
SAU:9589
|
SA |
|
G
|
Greentech Technology International Ltd
HKEX:195
|
HK |
|
Kidztech Holdings Ltd
HKEX:6918
|
CN |
Emmaus Life Sciences Inc
Emmaus Life Sciences, Inc. operates as a biopharmaceutical company. The company is headquartered in Torrance, California and currently employs 58 full-time employees. The company went IPO on 2000-05-09. The Company’s lead product, Endari was approved by the United States Food and Drug Administration (FDA) to reduce the acute complications of sickle cell disease (SCD) in adult and pediatric patients five years of age and older. Endari has received Orphan Drug designation from the FDA and Orphan Medicinal designation from the European Commission. Endari’s safety profile was like the placebo and Endari was well-tolerated in pediatric and adult patients alike. Its product pipeline includes ELS001/ELS007, ELS004, ELS005, ELS003 and ELS002. The Company’s subsidiaries include EMI Holding, Inc., Emmaus Medical, Inc., Emmaus Medical Japan, Inc., Newfield Nutrition Corporation, Emmaus Medical Europe Limited, Emmaus Medical Europe Limited and Emmaus Life Sciences, Co. Ltd.
Emmaus Life Sciences, Inc. operates as a biopharmaceutical company. The company is headquartered in Torrance, California and currently employs 58 full-time employees. The company went IPO on 2000-05-09. The Company’s lead product, Endari was approved by the United States Food and Drug Administration (FDA) to reduce the acute complications of sickle cell disease (SCD) in adult and pediatric patients five years of age and older. Endari has received Orphan Drug designation from the FDA and Orphan Medicinal designation from the European Commission. Endari’s safety profile was like the placebo and Endari was well-tolerated in pediatric and adult patients alike. Its product pipeline includes ELS001/ELS007, ELS004, ELS005, ELS003 and ELS002. The Company’s subsidiaries include EMI Holding, Inc., Emmaus Medical, Inc., Emmaus Medical Japan, Inc., Newfield Nutrition Corporation, Emmaus Medical Europe Limited, Emmaus Medical Europe Limited and Emmaus Life Sciences, Co. Ltd.
